Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Journal of the National Cancer Institute

Volumn 109, Issue 1, 2017, Pages

  Kotsopoulos, Joanne ^a   Huzarski, Tomasz ^b   Gronwald, Jacek ^b   Singer, Christian F ^c   Moller, Pal ^d   Lynch, Henry T ^e   Armel, Susan ^e   Karlan, Beth ^f   Foulkes, William D ^g,h   Neuhausen, Susan L ⁱ   Senter, Leigha ^j   Tung, Nadine ^k   Weitzel, Jeffrey N ^l   Eisen, Andrea ^j   Metcalfe, Kelly ^m   Eng, Charis ⁿ   Pal, Tuya ^o   Evans, Gareth ^p   Sun, Ping ^a   Lubinski, Jan ^a   Narod, Steven A ^a   more..

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Department of Obstetrics and Gynecology   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

^j CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^m DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

^o H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; GENE MUTATION; HAZARD RATIO; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARIECTOMY; PRIORITY JOURNAL; PROPHYLACTIC MASTECTOMY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TREATMENT DURATION; ADOLESCENT; AGE; AGED; BREAST NEOPLASMS; GENETICS; INCIDENCE; MIDDLE AGED; MUTATION; PROPHYLACTIC SURGICAL PROCEDURE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; OVARIECTOMY; PROPHYLACTIC SURGICAL PROCEDURES; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85014834392     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw177     Document Type: Article

References (26)

1. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(5): XXX-XXX.
2. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-87.
3. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international casecontrol study. J Clin Oncol. 2005;23(30):7491-7496.
4. Finch AP, Lubinski J, Moller P, et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol. 2014;32(15):1547-1553.
5. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
6. Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9): 1384-1392.
7. Metcalfe K, Lynch HT, Foulkes WD, et al. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015;1(3):306-313.
8. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingooophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl). 2012;8(5):543-555.
9. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingooophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008; 26(8):1331-1337.
10. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812-822.
11. Wacholder S. Bias in intervention studies that enroll patients from high-risk clinics. J Natl Cancer Inst. 2004;96(16):1204-1207.
12. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134-147.
13. Kotsopoulos J, Lubinski J, Salmena L, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2mutation carriers. Breast Cancer Res. 2012;14(2):R42.
14. Kotsopoulos J, Lubinski J, Lynch HT, et al. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005;16(6):667-674.
15. Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat. 2014;143(3):579-586.
16. Gronwald J, Robidoux A, Kim-Sing C, et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;146(2):421-427.
17. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-2256.
18. Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013; 31(25):3091-3099.
19. Kotsopoulos J, Huzarski T, Gronwald J, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat. 2016;155(2):365-373.
20. Gaudet MM, Gapstur SM, Sun J, et al. Oophorectomy and hysterectomy and cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. Obstet Gynecol. 2014;123(6):1247-1255.
21. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 1972;48(3):605-613.
22. Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105(5):709-722.
23. Freedman OC, Fletcher GG, Gandhi S, et al. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015;22(Suppl 1):S95-S113.
24. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009;113(5):1027-1037.
25. Parker WH, Jacoby V, Shoupe D, et al. Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl). 2009;5(5):565-576.
26. Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-1553.